Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Fiverr

The gig economy and diabetes care each represent rapidly-expanding total addressable markets. Fiverr isn't yet profitable, but its bottom line is improving as it grows its revenue and take rate.

Have $1,500? 2 Top Growth Stocks to Buy and Hold for the Long Haul

Etsy

Diabetes care and e-commerce are explosive industries set to see tremendous growth over the coming decade. DexCom is rolling out its latest product, and a new Medicare ruling should expand its total addressable market.

2 Incredible Growth Stocks to Buy Before the Next Bull Market

Alphabet

Palo Alto Networks

Since early 2022, everyday investors and Wall Street's brightest billionaire money managers have flocked to stocks enacting splits. The sustained competitive advantages offered by three stock-split stocks made them popular buys during the first quarter.

3 Stock-Split Stocks Billionaires Can't Stop Buying

Apple

DraftKings

Fortinet

Li Auto Inc.

NVIDIA

Spotify

Tractor Supply

Want to ride the hot hand of the market? Consider these nine momentum stocks that are climbing the charts this year.

9 Momentum Stocks to Buy Now

Abbott Labs

CNBC spoke with both Abbott and Dexcom about the technology inside continuous glucose monitors and how they see the technology expanding.

How Dexcom and Abbott are moving beyond diabetes with blood sugar monitoring

Airbnb

Concerns about the economy linger among investors, but some companies could show resilience. DexCom is serving a constant and growing need with its continuous glucose monitoring devices.

The Best Stocks to Invest $500 in Right Now

The introduction of the G7 sensor has been well received, with positive user feedback and an increase in subscribers, including new prescribers who were not previously using DexCom products. DXCM has benefited from the early initiation of Basal Medicare coverage, allowing them to tap into pent-up network demand.

DexCom: Growth Should Accelerate From Here

Teladoc

Teladoc remains one of the best telehealth prospects despite a rough past 12 months. DexCom is still just scratching the surface of a large opportunity related to continuous glucose monitoring.

Investing $1,000 in These 2 Top Growth Stocks Would Be a Brilliant Move

Cigna

Elevance Health Inc

Exact Sciences

Humana

Eli Lilly

UnitedHealth Group

The Baron Health Care Fund's first five years have been exceptional in every sense of the word. Launched in spring 2018, the fund has navigated around the COVID-19 pandemic, a biotech initial public offering market that boomed and fizzled, and D.C.

These stock pickers led the health-fund category over the past 5 years. Here's where they're investing now.

As more states legalize sports betting, DraftKings stock benefits from a greater pool of potential customers. DexCom's continuous glucose monitoring devices help diabetics keep track of their condition.

What Recession? These Companies Expect 20% Sales Growth This Year.

Rambus

Vipshop Hlds

Andrew Rocco combines fundamentals and technicals to bring you 3 top stocks on the verge of breaking out.

3 Stocks on the Verge of Breaking Out

Allegion

Comerica

Chipotle

Globe Life Inc

Molson Coors Brewing

Xylem

Profits are down at S&P 500 companies at large. But a few are putting up monster profit gains that seem to have no bounds.

8 Stocks' Monster Profit Growth Can't Be Contained

These five stocks offer investors a variety of options across multiple sectors. The post S&P 500 Medtech Play DexCom Leads Five Stocks Near Buy Points appeared first on Investor's Business Daily.

S&P 500 Medtech Play DexCom Leads Five Stocks Near Buy Points

Dexcom stock rebounds as glucose monitor maker sees expanding market. The med tech raised revenue guidance in its Q1 earnings report.

Dexcom Shows Strength As Glucose Monitor Attracts Buyers

KAGOSHIMA, Japan--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM System and will highlight the latest clinical evidence that continues to demonstrate the effectiveness of Dexcom CGM during the 66th Annual Meeting of the Japan Diabetes Society held May 11-13, 2023 in Kagoshima, Japan. Dexcom G6 uses a small, wearable sensor and tra.

Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society

GE HealthCare Technologies Inc

Medtronic

Increasingly, technologies other than drugs are working to improve patient health. From diagnostic systems like MRIs and CAT scans to high-tech glucose monitoring systems to devices that destroy tumors, medicine makes use of many such technologies.

3 HealthTech Stocks to Watch as Digital Health Transforms the Industry

SAN DIEGO--(BUSINESS WIRE)--Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028.

Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028

EDINBURGH, Scotland--(BUSINESS WIRE)--Dexcom rtCGM is associated with significant improvements over patients' lifetimes and is likely to be cost-saving to the NHS.

Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests

SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes.

Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes

Dexcom recently reported results from the first quarter of 2023 and reactions were mixed. Wall Street analysts cheered but shares of Dexcom fell a couple of percentage points.

Is Dexcom a Good Stock to Buy Now?

DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

DexCom (DXCM) Q1 Earnings Beat Estimates, Volumes Remain Strong

Dexcom lagged the most bullish expectations for its adjusted first-quarter earnings, but otherwise beat. Still, Dexcom stock skidded Friday.

Dexcom's Sales Growth Is Slowing, And The Top 2% Stock Just Skidded

Dexcom, Inc. (DXCM) Q1 2023 Earnings Call Transcript.

Dexcom, Inc. (DXCM) Q1 2023 Earnings Call Transcript

DexCom (DXCM) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.08 per share a year ago.

DexCom (DXCM) Q1 Earnings and Revenues Beat Estimates

Dexcom stock dipped a fraction late Thursday after the diabetes devices giant beat first-quarter expectations and raised its outlook. The post Top 2% Stock Dexcom Easily Beats First-Quarter Expectations, Boosts Outlook appeared first on Investor's Business Daily.

News for DexCom Stock (DXCM)